Tilray Clocks 43% Sales Growth In Q1

Loading...
Loading...
  • Tilray Inc TLRY has reported Q1 FY22 sales of $168 million, +43% Y/Y, missing the consensus of $172.6 million.
  • The increase was driven by a 38% Y/Y growth in net cannabis revenue to $70 million.
  • Q1 EPS loss $(0.08) came in line with expectations.
  • Tilray reported a wider operating loss of $(68.5) million compared to $(8.5) million in the prior-year quarter, primarily due to amortization and transaction costs.
  • Adjusted EBITDA reached $12.7 million, +58% Y/Y. Adjusted EBITDA normalized for Aphria’s production costs is approximately $17 million.
  • Gross profit increased 46% to $51 million from $35 million in the prior year quarter. Adjusted gross margin in the cannabis segment was at 43%.
  • The company is on track for at least $80 million in cost savings from Aphria and Tilray business combination synergies.
  • Related: Tilray CEO Received Nearly $30M In Compensation In Calendar 2021, $13.2M In Cash Bonuses...So Far.
  • Price Action: TLRY stock is up 0.46% at $10.84 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...